Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
2000 Turkeys
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
2000 Turkeys
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
17 Education & Technology Group Inc. - American Depositary Shares
Adient plc Ordinary Shares
Adit Edtech Acquisition Corp
Americann Inc
Autohome Inc. American Depositary Shares
CPS Technologies Corp. - Common Stock
Digital Currency X Technology Inc. - Class A Ordinary Shares
Dynatrace, Inc. Common Stock
Eagle Point Credit Company Inc. 8.00% Series F Term Preferred Stock due 2029
Eshallgo Inc. - Class A Ordinary Shares
Gamehaus Holdings Inc. - Class A Ordinary Shares
Hadron Energy, Inc. - Common Stock
Indaptus Therapeutics, Inc. - Common Stock
Ionic Digital Inc. - Class A Common Stock
Kolibri Global Energy Inc
MGM Growth Properties LLC Class A common shares representing limited liability c
Meg Energy Corp
Profound Medical Corp. - common stock
Trinity Capital Inc. - Common Stock
WaterBridge Infrastructure LLC Class A Shares Representing Limited Liability
Xcel Brands, Inc - Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by CuraSen Therapeutics, Inc.
Phase 2a Clinical Data Show CuraSen Therapeutics’ CuraAX (CST-3056) Met Primary Endpoint Demonstrating Statistically Significant Improvement in Standing Systolic Blood Pressure in Patients with Neurogenic Orthostatic Hypotension (nOH)
November 12, 2026
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics to Present Late-Breaking, Phase 2a Exploratory Data with CuraAX (CST-3056) in Patients with Neurogenic Orthostatic Hypotension (nOH) at the 37th International Symposium on the Autonomic Nervous System
November 05, 2026
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium
November 10, 2025
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study
October 23, 2025
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial
February 20, 2025
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer
October 15, 2024
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference
March 07, 2024
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease
October 09, 2023
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference
March 30, 2023
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment
December 19, 2022
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease
September 07, 2022
From
CuraSen Therapeutics, Inc.
Via
Business Wire
CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease
November 09, 2021
From
CuraSen Therapeutics, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today